Bailey Sue 4

4 · Emergent BioSolutions Inc. · Filed Nov 29, 2018

Form 4

Period: 2018-11-27

Director

Transactions

Exercise/Conversion
Common Stock
2018-11-27$20.08/sh+1,579$31,706→ 50,551 total
Sale
Common Stock
2018-11-27$69.62/sh−1,579$109,930→ 48,972 total
Exercise/Conversion
Common Stock
2018-11-27$13.00/sh+4,736$61,568→ 53,708 total
Sale
Common Stock
2018-11-27$69.62/sh−3,158$219,859→ 48,972 total
Exercise/Conversion
Stock Option (Right to buy)
2018-11-27−4,736→ 0 total
Exercise: $13.00Exp: 2020-05-22→ Common Stock (4,736 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2018-11-27−8,244→ 0 total
Exercise: $18.64Exp: 2021-05-21→ Common Stock (8,244 underlying)
Sale
Common Stock
2018-11-27$69.62/sh−8,244$573,945→ 48,972 total
Exercise/Conversion
Stock Option (Right to buy)
2018-11-27−1,579→ 0 total
Exercise: $20.08Exp: 2021-05-18→ Common Stock (1,579 underlying)
Exercise/Conversion
Common Stock
2018-11-27$18.64/sh+8,244$153,668→ 57,216 total
Sale
Common Stock
2018-11-27$69.62/sh−4,736$329,719→ 48,972 total
Exercise/Conversion
Common Stock
2018-11-27$13.37/sh+3,158$42,222→ 52,130 total
Exercise/Conversion
Stock Option (Right to buy)
2018-11-27−3,158→ 0 total
Exercise: $13.37Exp: 2019-05-16→ Common Stock (3,158 underlying)

Footnotes (3)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.05, inclusive.
[F2]Consists of an option granted under the company's stock incentive plan as amended and restated.
[F3]The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

Documents

1 file